<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173819</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI C100</org_study_id>
    <nct_id>NCT04173819</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults</brief_title>
  <official_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetics of two&#xD;
      broadly neutralizing monoclonal human antibodies (bNAbs), 3BNC117-LS-J, which targets the CD4&#xD;
      binding site on HIV-1 envelope protein, and 10-1074-LS-J which targets the V3 loop of HIV-1&#xD;
      envelope protein. The hypothesis is that the two antibodies will be safe for healthy HIV-1&#xD;
      uninfected adults when co-administered subcutaneously or intravenously and, after&#xD;
      subcutaneous administration in the optimal ratio, each antibody will maintain serum levels&#xD;
      &gt;10 Âµg/ml for at least 3 months in HIV-uninfected participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a randomized, double-blind, placebo-controlled Phase 1/2 study intended to evaluate the safety and pharmacokinetics of 10-1074-LS-J and 3BNC117-LS-J, alone or in combination, in healthy HIV-uninfected individuals.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Proportion of participants with solicited and treatment-related unsolicited adverse events and their duration.</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with serious adverse events (SAEs) throughout the study period that are considered related to investigational product and their duration.</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of each antibody in each group at multiple timepoints along with participant characteristics (e.g. sex, weight, and BMI)</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The ratio of 3BNC117-LS-J to 10-1074-LS-J that, when injected SC, will maintain similar levels of each bNAb at steady state.</measure>
    <time_frame>92 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of anti-3BNC117-LS-J antibodies in each group at multiple timepoints.</measure>
    <time_frame>92 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of anti-10-1074-LS-J antibodies in each group at multiple timepoints.</measure>
    <time_frame>92 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Agent, abdominal subcutaneous injection, 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent, abdominal subcutaneous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent intravenous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent intravenous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined agent intravenous injection 10:2 ratio for Ab:placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection combined ratio 1 with loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in abdomen combined ratio 2 with loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in abdomen combined ratio 3 with loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in abdomen combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection in arm combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3BNC117-LS-J</intervention_name>
    <description>300mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10-1074-LS-J</intervention_name>
    <description>300mg</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J</intervention_name>
    <description>30mg/kg of each</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1</intervention_name>
    <description>Total ~300 mg (&lt; 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2</description>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2</intervention_name>
    <description>Total ~300 mg (&lt; 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2</description>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3</intervention_name>
    <description>Total ~300 mg (&lt; 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2</description>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Saline</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Buffer Solution</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female individuals, as assessed by a medical history, physical exam,&#xD;
             and laboratory tests&#xD;
&#xD;
          -  At least 18 years of age on the day of screening and have not reached their 46th&#xD;
             birthday on the day of the first administration&#xD;
&#xD;
          -  Willing to undergo HIV testing, risk reduction counseling and receive HIV test&#xD;
             results; committed to maintaining low-risk behavior for the trial duration&#xD;
&#xD;
          -  Willing to comply with the requirements of the protocol and available for follow-up&#xD;
             for the planned duration of the study&#xD;
&#xD;
          -  All male and female participants of reproductive potential who are engaging in sexual&#xD;
             activity that could lead to pregnancy must commit to use an effective method of&#xD;
             contraception from enrollment until 9 months after the last administration&#xD;
&#xD;
          -  Willing to forgo donations of blood, or any other tissues during the study following&#xD;
             confirmation of study eligibility and, for those who test HIV-positive due to&#xD;
             antibody-induced seropositivity, until the anti-HIV antibody titers become&#xD;
             undetectable on HIV tests used in the community&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed HIV infection&#xD;
&#xD;
          -  Reported risk for HIV infection within 6 months prior to investigational product&#xD;
             administration, as defined by: Unprotected sexual intercourse with a known&#xD;
             HIV-infected person, a partner known to be at high risk for HIV infection and/or a&#xD;
             casual partner (i.e. no continuing established relationship), engaged in sex work,&#xD;
             frequent excessive daily alcohol use or frequent binge drinking or any other use of&#xD;
             illicit drugs, history of newly-acquired syphilis, gonorrhea, non-gonococcal&#xD;
             urethritis, HSV-2, chlamydia, pelvic inflammatory disease (PID), trichomonas,&#xD;
             mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid,&#xD;
             or hepatitis B or hepatitis C, three or more sexual partners&#xD;
&#xD;
          -  Any clinically significant acute or chronic medical condition that is considered&#xD;
             progressive or in the opinion of the investigator makes the participant unsuitable for&#xD;
             participation in the study&#xD;
&#xD;
          -  Infectious disease diagnosis: Hepatitis B infection as measured by HbsAg and/or PCR,&#xD;
             Hepatitis C infection (US: HCV RNA positive, or interferon-alpha treatment for&#xD;
             hepatitis C infection in the past year, or interferon-alpha-free treatment for&#xD;
             hepatitis C infection completed in the past 6 months; Africa: HCV Ab positive and/or&#xD;
             PCR positive), active syphilis (positive RPR confirmed by TPHA)&#xD;
&#xD;
          -  Receipt of blood transfusion or blood-derived products within the previous 3 months&#xD;
&#xD;
          -  Participation in another clinical trial of an investigational product currently,&#xD;
             within the previous 3 months or expected participation during this study (Concurrent&#xD;
             participation in an observational trial not requiring blood or tissue sample&#xD;
             collection is not an exclusion)&#xD;
&#xD;
          -  Psychiatric condition that compromises safety of the participant and precludes&#xD;
             compliance with the protocol. Specifically excluded are persons with psychoses within&#xD;
             the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture&#xD;
             within the past 3 years&#xD;
&#xD;
          -  Body mass index (BMI) &gt;40&#xD;
&#xD;
          -  Active tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dagna Laufer, MD</last_name>
    <phone>212-328-7459</phone>
    <email>Dlaufer@iavi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Baden, MD</last_name>
      <email>LBADEN@BWH.HARVARD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Caskey, MD</last_name>
      <phone>212-327-7396</phone>
      <email>mcaskey@mail.rockefeller.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Louis</last_name>
      <phone>425-610-6448</phone>
      <email>info@seattlevaccines.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Partners in Health Research and Development</name>
      <address>
        <city>Thika</city>
        <state>Kiambu</state>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nelly Mugo, MMED</last_name>
      <email>nwamba@csrtkenya.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative - Institute of Clinical Research</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaudensia Mutua, MD</last_name>
      <phone>+25472220417</phone>
      <email>gmutua@kaviunion.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Family Health Research</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne Karita, MD, MSc, MPH</last_name>
      <email>EKarita@rzhrg-mail.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sinead Delaney-Moretlwe, MD</last_name>
      <email>sdelaney@wrhi.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uganda Virus Research Institute</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brenda Okech, PhD</last_name>
      <email>bokech@iavi.or.ug</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Institute Kasangati</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Mujugira, MD</last_name>
      <email>mujugira@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Rwanda</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://iavi.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

